Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06250335 · ClinicalTrials.gov registry record · Phase 2
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
A Phase 2 study of ICB-refractory Melanoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT06250335 is a Phase 2 study of ICB-refractory Melanoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06250335, a Phase 2 study of ICB-refractory Melanoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of their standard care.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- OTHER Prebiotic Food-Enriched Diet
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2029-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06250335
The ClinicalTrials.gov registry entry for NCT06250335 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ICB-refractory Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06250335 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06250335 about?
NCT06250335 is a clinical study titled "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients". To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of their standard care.
What is the current status of trial NCT06250335?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-03-01. Estimated completion is 2029-01-23.
What conditions does trial NCT06250335 study?
This clinical trial studies the following conditions: ICB-refractory Melanoma.
What interventions are being tested in trial NCT06250335?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Prebiotic Food-Enriched Diet (OTHER).
Who is sponsoring clinical trial NCT06250335?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06250335 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.